Clarissa Desjardins

La Fondation de l'innovation du Nouveau-Brunswick is an Independent Venture Capital firm founded in 2003. La Fondation de l'innovation du Nouveau-Brunswick is headquartered in Fredericton.

Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada.

Part of Nen Tm Life Science Products, Inc., Advanced Bioconcept Ltd. is a Canadian company that makes proprietary, fluorescent labeled peptides. The company is based in Montréal, Canada. The company was founded by Clarissa Desjardins. Advanced Bioconcept was acquired by Nen Tm Life Science Products, Inc. on September 25, 1998.

Caprion Pharmaceuticals, Inc. discovered and developed pharmaceutical products. It offered a proprietary therapeutic pipeline in oncology and infectious diseases. Caprion Pharmaceuticals proteomics discovery technologies used to enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly enhance clinical development productivity and decision making. The company was founded in 1998 and was headquartered in Montreal, Canada.

Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada.

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.